BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1054 related articles for article (PubMed ID: 30981783)

  • 1. Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study.
    Ferrua F; Cicalese MP; Galimberti S; Giannelli S; Dionisio F; Barzaghi F; Migliavacca M; Bernardo ME; Calbi V; Assanelli AA; Facchini M; Fossati C; Albertazzi E; Scaramuzza S; Brigida I; Scala S; Basso-Ricci L; Pajno R; Casiraghi M; Canarutto D; Salerio FA; Albert MH; Bartoli A; Wolf HM; Fiori R; Silvani P; Gattillo S; Villa A; Biasco L; Dott C; Culme-Seymour EJ; van Rossem K; Atkinson G; Valsecchi MG; Roncarolo MG; Ciceri F; Naldini L; Aiuti A
    Lancet Haematol; 2019 May; 6(5):e239-e253. PubMed ID: 30981783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome.
    Hacein-Bey Abina S; Gaspar HB; Blondeau J; Caccavelli L; Charrier S; Buckland K; Picard C; Six E; Himoudi N; Gilmour K; McNicol AM; Hara H; Xu-Bayford J; Rivat C; Touzot F; Mavilio F; Lim A; Treluyer JM; Héritier S; Lefrère F; Magalon J; Pengue-Koyi I; Honnet G; Blanche S; Sherman EA; Male F; Berry C; Malani N; Bushman FD; Fischer A; Thrasher AJ; Galy A; Cavazzana M
    JAMA; 2015 Apr; 313(15):1550-63. PubMed ID: 25898053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B-cell reconstitution after lentiviral vector-mediated gene therapy in patients with Wiskott-Aldrich syndrome.
    Castiello MC; Scaramuzza S; Pala F; Ferrua F; Uva P; Brigida I; Sereni L; van der Burg M; Ottaviano G; Albert MH; Grazia Roncarolo M; Naldini L; Aiuti A; Villa A; Bosticardo M
    J Allergy Clin Immunol; 2015 Sep; 136(3):692-702.e2. PubMed ID: 25792466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome.
    Aiuti A; Biasco L; Scaramuzza S; Ferrua F; Cicalese MP; Baricordi C; Dionisio F; Calabria A; Giannelli S; Castiello MC; Bosticardo M; Evangelio C; Assanelli A; Casiraghi M; Di Nunzio S; Callegaro L; Benati C; Rizzardi P; Pellin D; Di Serio C; Schmidt M; Von Kalle C; Gardner J; Mehta N; Neduva V; Dow DJ; Galy A; Miniero R; Finocchi A; Metin A; Banerjee PP; Orange JS; Galimberti S; Valsecchi MG; Biffi A; Montini E; Villa A; Ciceri F; Roncarolo MG; Naldini L
    Science; 2013 Aug; 341(6148):1233151. PubMed ID: 23845947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial.
    Sessa M; Lorioli L; Fumagalli F; Acquati S; Redaelli D; Baldoli C; Canale S; Lopez ID; Morena F; Calabria A; Fiori R; Silvani P; Rancoita PM; Gabaldo M; Benedicenti F; Antonioli G; Assanelli A; Cicalese MP; Del Carro U; Sora MG; Martino S; Quattrini A; Montini E; Di Serio C; Ciceri F; Roncarolo MG; Aiuti A; Naldini L; Biffi A
    Lancet; 2016 Jul; 388(10043):476-87. PubMed ID: 27289174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of gene therapy for Wiskott-Aldrich syndrome using a WAS promoter/cDNA-containing lentiviral vector and nonlethal irradiation.
    Dupré L; Marangoni F; Scaramuzza S; Trifari S; Hernández RJ; Aiuti A; Naldini L; Roncarolo MG
    Hum Gene Ther; 2006 Mar; 17(3):303-13. PubMed ID: 16544979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report.
    Burroughs LM; Petrovic A; Brazauskas R; Liu X; Griffith LM; Ochs HD; Bleesing JJ; Edwards S; Dvorak CC; Chaudhury S; Prockop SE; Quinones R; Goldman FD; Quigg TC; Chandrakasan S; Smith AR; Parikh S; Dávila Saldaña BJ; Thakar MS; Phelan R; Shenoy S; Forbes LR; Martinez C; Chellapandian D; Shereck E; Miller HK; Kapoor N; Barnum JL; Chong H; Shyr DC; Chen K; Abu-Arja R; Shah AJ; Weinacht KG; Moore TB; Joshi A; DeSantes KB; Gillio AP; Cuvelier GDE; Keller MD; Rozmus J; Torgerson T; Pulsipher MA; Haddad E; Sullivan KE; Logan BR; Kohn DB; Puck JM; Notarangelo LD; Pai SY; Rawlings DJ; Cowan MJ
    Blood; 2020 Jun; 135(23):2094-2105. PubMed ID: 32268350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lentiviral vector-mediated gene transfer in T cells from Wiskott-Aldrich syndrome patients leads to functional correction.
    Dupré L; Trifari S; Follenzi A; Marangoni F; Lain de Lera T; Bernad A; Martino S; Tsuchiya S; Bordignon C; Naldini L; Aiuti A; Roncarolo MG
    Mol Ther; 2004 Nov; 10(5):903-15. PubMed ID: 15509508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome.
    Labrosse R; Chu JI; Armant MA; Everett JK; Pellin D; Kareddy N; Frelinger AL; Henderson LA; O'Connell AE; Biswas A; Coenen-van der Spek J; Miggelbrink A; Fiorini C; Adhikari H; Berry CC; Cantu VA; Fong J; Jaroslavsky J; Karadeniz DF; Li QZ; Reddy S; Roche AM; Zhu C; Whangbo JS; Dansereau C; Mackinnon B; Morris E; Koo SM; London WB; Baris S; Ozen A; Karakoc-Aydiner E; Despotovic JM; Forbes Satter LR; Saitoh A; Aizawa Y; King A; Nguyen MAT; Vu VDU; Snapper SB; Galy A; Notarangelo LD; Bushman FD; Williams DA; Pai SY
    Blood; 2023 Oct; 142(15):1281-1296. PubMed ID: 37478401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott-Aldrich syndrome.
    Magnani A; Semeraro M; Adam F; Booth C; Dupré L; Morris EC; Gabrion A; Roudaut C; Borgel D; Toubert A; Clave E; Abdo C; Gorochov G; Petermann R; Guiot M; Miyara M; Moshous D; Magrin E; Denis A; Suarez F; Lagresle C; Roche AM; Everett J; Trinquand A; Guisset M; Bayford JX; Hacein-Bey-Abina S; Kauskot A; Elfeky R; Rivat C; Abbas S; Gaspar HB; Macintyre E; Picard C; Bushman FD; Galy A; Fischer A; Six E; Thrasher AJ; Cavazzana M
    Nat Med; 2022 Jan; 28(1):71-80. PubMed ID: 35075289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and emerging treatment options for Wiskott-Aldrich syndrome.
    Worth AJ; Thrasher AJ
    Expert Rev Clin Immunol; 2015; 11(9):1015-32. PubMed ID: 26159751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematopoietic-specific lentiviral vectors circumvent cellular toxicity due to ectopic expression of Wiskott-Aldrich syndrome protein.
    Toscano MG; Frecha C; Benabdellah K; Cobo M; Blundell M; Thrasher AJ; García-Olivares E; Molina IJ; Martin F
    Hum Gene Ther; 2008 Feb; 19(2):179-97. PubMed ID: 18240968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lentiviral gene therapy corrects platelet phenotype and function in patients with Wiskott-Aldrich syndrome.
    Sereni L; Castiello MC; Di Silvestre D; Della Valle P; Brombin C; Ferrua F; Cicalese MP; Pozzi L; Migliavacca M; Bernardo ME; Pignata C; Farah R; Notarangelo LD; Marcus N; Cattaneo L; Spinelli M; Giannelli S; Bosticardo M; van Rossem K; D'Angelo A; Aiuti A; Mauri P; Villa A
    J Allergy Clin Immunol; 2019 Sep; 144(3):825-838. PubMed ID: 30926529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access.
    Fumagalli F; Calbi V; Natali Sora MG; Sessa M; Baldoli C; Rancoita PMV; Ciotti F; Sarzana M; Fraschini M; Zambon AA; Acquati S; Redaelli D; Attanasio V; Miglietta S; De Mattia F; Barzaghi F; Ferrua F; Migliavacca M; Tucci F; Gallo V; Del Carro U; Canale S; Spiga I; Lorioli L; Recupero S; Fratini ES; Morena F; Silvani P; Calvi MR; Facchini M; Locatelli S; Corti A; Zancan S; Antonioli G; Farinelli G; Gabaldo M; Garcia-Segovia J; Schwab LC; Downey GF; Filippi M; Cicalese MP; Martino S; Di Serio C; Ciceri F; Bernardo ME; Naldini L; Biffi A; Aiuti A
    Lancet; 2022 Jan; 399(10322):372-383. PubMed ID: 35065785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ubiquitous high-level gene expression in hematopoietic lineages provides effective lentiviral gene therapy of murine Wiskott-Aldrich syndrome.
    Astrakhan A; Sather BD; Ryu BY; Khim S; Singh S; Humblet-Baron S; Ochs HD; Miao CH; Rawlings DJ
    Blood; 2012 May; 119(19):4395-407. PubMed ID: 22431569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial.
    Beelen DW; Trenschel R; Stelljes M; Groth C; Masszi T; Reményi P; Wagner-Drouet EM; Hauptrock B; Dreger P; Luft T; Bethge W; Vogel W; Ciceri F; Peccatori J; Stölzel F; Schetelig J; Junghanß C; Grosse-Thie C; Michallet M; Labussiere-Wallet H; Schaefer-Eckart K; Dressler S; Grigoleit GU; Mielke S; Scheid C; Holtick U; Patriarca F; Medeot M; Rambaldi A; Micò MC; Niederwieser D; Franke GN; Hilgendorf I; Winkelmann NR; Russo D; Socié G; Peffault de Latour R; Holler E; Wolff D; Glass B; Casper J; Wulf G; Menzel H; Basara N; Bieniaszewska M; Stuhler G; Verbeek M; Grass S; Iori AP; Finke J; Benedetti F; Pichlmeier U; Hemmelmann C; Tribanek M; Klein A; Mylius HA; Baumgart J; Dzierzak-Mietla M; Markiewicz M
    Lancet Haematol; 2020 Jan; 7(1):e28-e39. PubMed ID: 31606445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. When
    Jin YY; Wu J; Chen TX; Chen J
    Front Immunol; 2019; 10():1549. PubMed ID: 31354712
    [No Abstract]   [Full Text] [Related]  

  • 18. Development of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome.
    Boztug K; Dewey RA; Klein C
    Curr Opin Mol Ther; 2006 Oct; 8(5):390-5. PubMed ID: 17078381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wiskott-Aldrich syndrome: diagnosis, clinical and laboratory manifestations, and treatment.
    Ochs HD; Filipovich AH; Veys P; Cowan MJ; Kapoor N
    Biol Blood Marrow Transplant; 2009 Jan; 15(1 Suppl):84-90. PubMed ID: 19147084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study.
    Cohen S; Roy J; Lachance S; Delisle JS; Marinier A; Busque L; Roy DC; Barabé F; Ahmad I; Bambace N; Bernard L; Kiss T; Bouchard P; Caudrelier P; Landais S; Larochelle F; Chagraoui J; Lehnertz B; Corneau S; Tomellini E; van Kampen JJA; Cornelissen JJ; Dumont-Lagacé M; Tanguay M; Li Q; Lemieux S; Zandstra PW; Sauvageau G
    Lancet Haematol; 2020 Feb; 7(2):e134-e145. PubMed ID: 31704264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.